Telomir Pharmaceuticals, Inc. Common Stock
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TELO research report →
Companytelomirpharma.com
Telomir Pharmaceuticals, Inc. , a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. It develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy recovery by interrupting and preventing the interleukin-17 induced inflammatory pathways.
- CEO
- Erez Aminov
- IPO
- 2019
- Employees
- 1
- HQ
- Baltimore, FL, US
Price Chart
Valuation
- Market Cap
- $45.04M
- P/E
- -4.88
- P/S
- 0.00
- P/B
- 9.08
- EV/EBITDA
- -4.26
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -201.23%
- ROIC
- -189.28%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-10,413,205 · 37.01%
- EPS
- $-0.33 · 41.07%
- Op Income
- $-10,538,849
- FCF YoY
- 27.26%
Performance & Tape
- 52W High
- $3.10
- 52W Low
- $1.05
- 50D MA
- $1.32
- 200D MA
- $1.37
- Beta
- -0.21
- Avg Volume
- 135.29K
Get TickerSpark's AI analysis on TELO
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 22, 26 | Aminov Erez | other | 7,319,710 |
| Sep 29, 25 | MIRA PHARMACEUTICALS, INC. | other | 0 |
| May 15, 25 | Weichselbaum Alan | other | 50,000 |
| May 28, 25 | Aminov Erez | other | 2,000,000 |
| May 28, 25 | Aminov Erez | other | 400,000 |
| Dec 31, 24 | Aminov Erez | other | 0 |
| Nov 21, 24 | Bay Shore Trust | other | 100,000 |
| Aug 27, 24 | Yanez Michelle | other | 200,000 |
Our TELO Coverage
We haven't published any research on TELO yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate TELO Report →